Search
  • About Us
    • Company profile
    • Team
    • Board of Directors
    • Scientific Advisory Board
  • Pipeline
    • Pipeline overview
    • CDNF
    • Next generation xCDNF
    • Lymfactin
    • Scientific publications
  • Investors
    • Investors
    • Releases
    • Analyst Coverage
    • Financial Calendar
    • General Meetings
    • Financial Information
    • Share Information
    • Share Monitor
    • Investor Relations
    • Corporate Governance
  • News & Events
    • Herantis in the News
    • Events
    • Releases
    • Public materials
    • Video Presentations
    • Newsletter
  • Patients
    • Overview & Contact Us
    • Parkinson’s Disease
    • Lymphedema
    • Community Resources
  • Contact
Search

TreatER webcast seminar – World’s first clinical trial with CDNF: Aiming for a breakthrough in Parkinson's

  1. Welcome and opening words. Henri Huttunen, Chief Scientific Officer, Herantis Pharma Plc    Video (4:12 min)
  2. Neurotrophic Factors in clinical trials – Brief look to the recent past, present and years to come. Mart Saarma, Professor, Institute of Biotechnology, University of Helsinki     Video (17:46 min)    Slides (pdf)
  3. Cerebral Dopamine Neurotrophic Factor (CDNF)– Potential in prevention of dopamine neuron degeneration and stimulation ofneuron regeneration. Henri Huttunen, Chief Scientific Officer, Herantis Pharma Plc     Video (21:23 min)    Slides (pdf)
  4. First break with 10 min exercise. Josefa Domingos, Specialist Physiotherapist & EPDA Board Member     Video (9:26 min)
  5. CDNF in the first-in-human clinical trial (Safety) –12-month clinical data on the monthly infusions of CDNF directly into a targeted area of the brain of people living with Parkinson’s. Magnus Sjögren, Chief Medical Officer, Herantis Pharma Plc    Video (24:18 min)    Slides (pdf)
  6. CDNF in the first-in-human clinical trial (Efficacy) –12-month clinical data on the monthly infusions of CDNF directly into a targeted area of the brain of people living with Parkinson’s. Per Svenningsson, Principal Investigator, Karolinska University Hospital     Video (23:05 min)     Slides (pdf)
  7. Second break with 10 min exercise. Josefa Domingos, Specialist Physiotherapist & EPDA Board Member     Video (9:11 min)
  8. Clinical data on the investigational drug delivery system used for the CDNF infusion. Jim Baker, Head of QA/RA and Clinical Affairs, Healthcare Division, Renishaw Plc     Video (17:30 min)     Slides (pdf)
  9. Panel discussion on CDNF development for Parkinson’s disease 
    • Per Svenningsson, Professor, Principal Investigator, Karolinska University Hospital
    • Håkan Widner, Professor, Department of Neurology, Skåne University Hospital
    • Filip Scheperjans, Adjunct Professor of Neurology, Helsinki University Hospital
    • Juha Rinne, Professor, Turku PET Centre
    • Göran Lind, Neurosurgeon, Karolinska University Hospital
    • Paul Skinner, General Manager, Renishaw Neuro Solutions Ltd
    • Craig Cook, CEO, Herantis Pharma Plc
    • Alan Whone, Consultant Senior Lecturer in Movement Disorder, University of Bristol    Video (48:16 mi
The CDNF clinical study is part of the TreatER project and has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 732386. For more information please visit the project website www.treater.eu.

HERANTIS PHARMA Plc
Bertel Jungin Aukio 1
FIN-02600 Espoo

Tel: +358 9 222 1195
Email: info (at) herantis.com
VAT number FI21986657

  • Legal notice
  • Privacy notice
  • Sign up for our bi-monthly newsletter

Copyright © HERANTIS PHARMA Plc. All rights reserved.

Cookies
This website uses cookies and Google Analytics. We use cookies and Google Analytics to adapt the website according to your preferences and to collect information about the use of the website. For more information regarding cookies we request you to review our privacy notice. The following terms and conditions are applied to the use of this website. By continuing to use this website you accept such terms and conditions.
OK
Privacy notice
Legal notice
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.